21. A compound which is 6-{[2-(5-cyclopropylpyridin-2-yl)cyclopropyl]methoxy}-2-methyl-N-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine or a pharmaceutically acceptable salt thereof.

22. A compound which is 2-methyl-N-((5-methylisoxazol-3-yl)methyl)-6-((2-(pyridin-2-yl)cyclopropyl)methoxy)-pyrimidin-4-amine or a pharmaceutically acceptable salt thereof.

23. A compound which is 2-amino-4-{[(1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}-6-{[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]amino}pyrimidine-5-carbonitrile or a pharmaceutically acceptable salt thereof.

24. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a compound of any one of the preceding claims or a pharmaceutically acceptable salt thereof.

25. A compound of any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof for use in medicine.

26. Use of a compound of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of ~~a disorder selected from psychotic disorders, delusional disorders and drug induced psychosis; anxiety disorders, movement disorders, mood disorders, neurodegenerative disorders and~~ schizophrenia.

27. A compound of any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof for use in treating a neurological or psychiatric disorder associated with PDE10 dysfunction in a mammalian patient.

28. A compound of any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof for use in treating a neurological or psychiatric disorder associated with